Product logins

Find logins to all Clarivate products below.


Obesity / Overweight – Landscape & Forecast – Disease Landscape & Forecast (G7)

Obesity is a significant and growing public health concern in the G7 countries. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, approved drugs are scarce compared with other chronic metabolic diseases, especially in Europe and Japan. However, the development pipeline is strengthening with novel agents that promise to address some of the limitations of current treatments. There is a huge market opportunity for antiobesity drugs that elicit greater and sustained weight loss and are safe, well tolerated, and affordable. However, given the prevalence of obesity, even if such agents are developed and approved, payers will likely need to restrict their access to limit the strain on finite healthcare budgets.

Questions answered

  • Which metabolic and central pathways have high potential as drug targets?
  • What is the prevalence of obesity in the major pharmaceutical markets under study?
  • How is obesity currently treated? What do experts think about Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) as treatments for obese / overweight patients?
  • What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
  • How will the obesity therapy market evolve over the next 10 years?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations

Table of contents


Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Rare Diseases and Orphan Drugs – Landscape & Forecast – Disease Landscape & Forecast (G7)
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…